Guardant Health (GH) PT Raised to $40 at Jefferies
Jefferies analyst Tycho Peterson raised the price target on Guardant Health (NASDAQ: GH) to $40.00 (from $32.00) while maintaining a Buy rating.
The analyst comments "After months of scrutiny on Shield, GH's core therapy selection business stole back some of the spotlight, as G360 helped the company deliver a +9% revenue beat (vs. Street), while FY24 guidance was raised +2% (+$15M midpoint). Looking ahead, 2H should benefit from continued strength in the core business, initial traction from the Shield launch (and higher than expected price) and a surveillance indication for Reveal in 4Q24/1H25. Reiterate Buy; PT to $40."